Dabocemagene autoficel

达博基奥菲赛

Report date: 2025/03/26 17:13:42

Base Information

Drug NameDabocemagene autoficel

Drug Alias NameGenetically modified human dermal fibroblast-collagen VIIFibroblast recessive dystrophic epidermolysis bullosa gene thearpyFibroblast recessive dystrophic epidermolysis bullosa cell therapyFibroblast epidermolysis bullosa cell therapyFibroblast epidermolysis bullosa gene therapy +[10]

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Source of cells > Skin biopsies-derivedCell and gene therapy > Cell therapy > Donor > Autologous +[4]

Mechanisms of ActionCOL7 gene transference

TargetsCollagen alpha-1(VII) chain

Therapy Area/IndicationsEpidermolysis Bullosa Dystrophica

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesFibrocell Science Inc

China Registration ClassN/A

Develop Information

Active CompaniesLigand Pharmaceuticals Inc Castle Creek Biosciences LLC

Inactive CompaniesN/A

Active IndicationsEpidermolysis Bullosa Dystrophica

Inactive IndicationsN/A

Other Information

ATC CodeN/A